--- 
layout: page 
image:
  feature: DaubEnginePatent.jpg
--- 
   <head>
      <title>2753-</title>
      <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
</head>
      <li><a href="index.html">Manual of Patent Examining Procedure</a></li>
      <li><a href="mpep-2700.html"><span>Chapter 2700</span></a></li>
      <li><span>Section 2753</span></li>  </ul>
      <div id="yui-main">
         <div class="yui-b">
            <div class="yui-g">  <div xmlns:bf="http://www.uspto.gov/bf" id="article">
               <div>
                  <div xmlns="" class="Section" id="d0e276403">
                     <h1 class="page-title">2753
                        &nbsp;&nbsp;
                        Application Contents [R-11.2013]
                     </h1>
                     <div id="d0e276407" class="CFR">
                        <h4 class="CFR"><i>37&nbsp;C.F.R.&nbsp;1.740 &nbsp;
                              
                              
                              
                              Formal requirements for application for extension of patent
                              term; correction of informalities.</i></h4>
                        <ul style="list-style-type: none;">
                           <li id="d0e276415" class="nobull">(a) An application for
                              extension of patent term must be made in writing to the Director. A formal
                              application for the extension of patent term must include:
                              <ul style="list-style-type: none;">
                                 <li id="" class="nobull">
                                    <p id=""></p>
                                 </li>
                                 <li id="d0e276420" class="nobull">(1) A complete
                                    identification of the approved product as by appropriate chemical and
                                    generic name, physical structure or characteristics;
                                 </li>
                                 <li id="d0e276424" class="nobull">(2) A complete
                                    identification of the Federal statute including the applicable provision
                                    of law under which the regulatory review occurred;
                                 </li>
                                 <li id="d0e276428" class="nobull">(3) An identification of
                                    the date on which the product received permission for commercial
                                    marketing or use under the provision of law under which the applicable
                                    regulatory review period occurred;
                                 </li>
                                 <li id="d0e276432" class="nobull">(4) In the case of a drug
                                    product, an identification of each active ingredient in the product and
                                    as to each active ingredient, a statement that it has not been previously
                                    approved for commercial marketing or use under the Federal Food, Drug,
                                    and Cosmetic Act, the Public Health Service Act, or the Virus-Serum-Toxin
                                    Act, or a statement of when the active ingredient was approved for
                                    commercial marketing or use (either alone or in combination with other
                                    active ingredients), the use for which it was approved, and the provision
                                    of law under which it was approved.
                                 </li>
                                 <li id="d0e276436" class="nobull">(5) A statement that the
                                    application is being submitted within the sixty day period permitted for
                                    submission pursuant to <b><a href="mpep-9020-appx-r.html#d0e332035">ยง 1.720(f)</a></b> and an
                                    identification of the date of the last day on which the application could
                                    be submitted;
                                 </li>
                                 <li id="d0e276440" class="nobull">(6) A complete
                                    identification of the patent for which an extension is being sought by
                                    the name of the inventor, the patent number, the date of issue, and the
                                    date of expiration;
                                 </li>
                                 <li id="d0e276444" class="nobull">(7) A copy of the patent
                                    for which an extension is being sought, including the entire
                                    specification (including claims) and drawings;
                                 </li>
                                 <li id="d0e276448" class="nobull">(8) A copy of any
                                    disclaimer, certificate of correction, receipt of maintenance fee
                                    payment, or reexamination certificate issued in the
                                    patent;
                                 </li>
                                 <li id="d0e276452" class="nobull">(9) A statement that the
                                    patent claims the approved product, or a method of using or manufacturing
                                    the approved product, and a showing which lists each applicable patent
                                    claim and demonstrates the manner in which at least one such patent claim
                                    reads on:
                                    <ul style="list-style-type: none;">
                                       <li id="" class="nobull">
                                          <p id=""></p>
                                       </li>
                                       <li id="d0e276456" class="nobull">(i) The approved
                                          product, if the listed claims include any claim to the approved
                                          product;
                                       </li>
                                       <li id="d0e276460" class="nobull">(ii) The method of
                                          using the approved product, if the listed claims include any claim
                                          to the method of using the approved product; and
                                       </li>
                                       <li id="d0e276464" class="nobull">(iii) The method of
                                          manufacturing the approved product, if the listed claims include
                                          any claim to the method of manufacturing the approved
                                          product;
                                       </li>
                                    </ul>
                                 </li>
                                 <li id="d0e276468" class="nobull">(10)  A statement
                                    beginning on a new page of the relevant dates and information pursuant to
                                    <b><a href="mpep-9015-appx-l.html#d0e303884">35&nbsp;U.S.C. 156(g)</a></b> in
                                    order to enable the Secretary of Health and Human Services or the
                                    Secretary of Agriculture, as appropriate, to determine the applicable
                                    regulatory review period as follows:
                                    <ul style="list-style-type: none;">
                                       <li id="" class="nobull">
                                          <p id=""></p>
                                       </li>
                                       <li id="d0e276475" class="nobull">(i) For a patent
                                          claiming a human drug, antibiotic, or human biological
                                          product:
                                          <ul style="list-style-type: none;">
                                             <li id="" class="nobull">
                                                <p id=""></p>
                                             </li>
                                             <li id="d0e276479" class="nobull">(A) The
                                                effective date of the investigational new drug (IND)
                                                application and the IND number;
                                             </li>
                                             <li id="d0e276483" class="nobull">(B) The date
                                                on which a new drug application (NDA) or a Product License
                                                Application (PLA) was initially submitted and the NDA or PLA
                                                number; and
                                             </li>
                                             <li id="d0e276487" class="nobull">(C) The date
                                                on which the NDA was approved or the Product License
                                                issued;
                                             </li>
                                          </ul>
                                       </li>
                                       <li id="d0e276491" class="nobull">(ii) For a patent
                                          claiming a new animal drug:
                                          <ul style="list-style-type: none;">
                                             <li id="" class="nobull">
                                                <p id=""></p>
                                             </li>
                                             <li id="d0e276495" class="nobull">(A) The date
                                                a major health or environmental effects test on the drug was
                                                initiated, and any available substantiation of that date, or
                                                the date of an exemption under subsection (j) of Section 512
                                                of the Federal Food, Drug, and Cosmetic Act became effective
                                                for such animal drug;
                                             </li>
                                             <li id="d0e276499" class="nobull">(B) The date
                                                on which a new animal drug application (NADA) was initially
                                                submitted and the NADA number; and
                                             </li>
                                             <li id="d0e276503" class="nobull">(C) The date
                                                on which the NADA was approved;
                                             </li>
                                          </ul>
                                       </li>
                                       <li id="d0e276507" class="nobull">(iii) For a patent
                                          claiming a veterinary biological product:
                                          <ul style="list-style-type: none;">
                                             <li id="" class="nobull">
                                                <p id=""></p>
                                             </li>
                                             <li id="d0e276511" class="nobull">(A) The date
                                                the authority to prepare an experimental biological product
                                                under the Virus-Serum-Toxin Act became
                                                effective;
                                             </li>
                                             <li id="d0e276515" class="nobull">(B) The date
                                                an application for a license was submitted under the
                                                Virus-Serum-Toxin Act; and
                                             </li>
                                             <li id="d0e276519" class="nobull">(C) The date
                                                the license issued;
                                             </li>
                                          </ul>
                                       </li>
                                       <li id="d0e276523" class="nobull">(iv) For a patent
                                          claiming a food or color additive:
                                          <ul style="list-style-type: none;">
                                             <li id="" class="nobull">
                                                <p id=""></p>
                                             </li>
                                             <li id="d0e276527" class="nobull">(A) The date
                                                a major health or environmental effects test on the additive
                                                was initiated and any available substantiation of that
                                                date;
                                             </li>
                                             <li id="d0e276531" class="nobull">(B) The date
                                                on which a petition for product approval under the Federal
                                                Food, Drug and Cosmetic Act was initially submitted and the
                                                petition number; and
                                             </li>
                                             <li id="d0e276535" class="nobull">(C) The date
                                                on which the FDA published a <i>Federal Register</i> notice listing the additive
                                                for use;
                                             </li>
                                          </ul>
                                       </li>
                                       <li id="d0e276542" class="nobull">(v) For a patent
                                          claiming a medical device:
                                          <ul style="list-style-type: none;">
                                             <li id="" class="nobull">
                                                <p id=""></p>
                                             </li>
                                             <li id="d0e276546" class="nobull">(A) The
                                                effective date of the investigational device exemption (IDE)
                                                and the IDE number, if applicable, or the date on which the
                                                applicant began the first clinical investigation involving
                                                the device, if no IDE was submitted, and any available
                                                substantiation of that date;
                                             </li>
                                             <li id="d0e276550" class="nobull">(B) The date
                                                on which the application for product approval or notice of
                                                completion of a product development protocol under Section
                                                515 of the Federal Food, Drug and Cosmetic Act was initially
                                                submitted and the number of the application;
                                                and
                                             </li>
                                             <li id="d0e276554" class="nobull">(C) The date
                                                on which the application was approved or the protocol
                                                declared to be completed;
                                             </li>
                                          </ul>
                                       </li>
                                    </ul>
                                 </li>
                                 <li id="d0e276558" class="nobull">(11)  A brief description
                                    beginning on a new page of the significant activities undertaken by the
                                    marketing applicant during the applicable regulatory review period with
                                    respect to the approved product and the significant dates applicable to
                                    such activities;
                                 </li>
                                 <li id="d0e276562" class="nobull">(12)  A statement
                                    beginning on a new page that in the opinion of the applicant the patent
                                    is eligible for the extension and a statement as to the length of
                                    extension claimed, including how the length of extension was
                                    determined;
                                 </li>
                                 <li id="d0e276569" class="nobull">(13)  A statement that
                                    applicant acknowledges a duty to disclose to the Director of the United
                                    States Patent and Trademark Office and the Secretary of Health and Human
                                    Services or the Secretary of Agriculture any information which is
                                    material to the determination of entitlement to the extension sought
                                    (<i>see</i><b><a href="mpep-9020-appx-r.html#d0e332404">ยง&nbsp;1.765</a></b>);
                                 </li>
                                 <li id="d0e276580" class="nobull">(14)  The prescribed fee
                                    for receiving and acting upon the application for extension (see
                                    <b><a href="mpep-9020-appx-r.html#d0e316217">ยง 1.20(j)</a></b>);
                                    and
                                 </li>
                                 <li id="d0e276587" class="nobull">(15)  The name, address,
                                    and telephone number of the person to whom inquiries and correspondence
                                    relating to the application for patent term extension are to be
                                    directed.
                                 </li>
                              </ul>
                           </li>
                           <li id="d0e276591" class="nobull">(b) The application under this
                              section must be accompanied by two additional copies of such application (for a
                              total of three copies).
                           </li>
                           <li id="d0e276595" class="nobull">(c) If an application for
                              extension of patent term is informal under this section, the Office will so
                              notify the applicant. The applicant has two months from the mail date of the
                              notice, or such time as is set in the notice, within which to correct the
                              informality. Unless the notice indicates otherwise, this time period may be
                              extended under the provisions of <b><a href="mpep-9020-appx-r.html#d0e323655">ยง
                                    1.136</a></b>.
                           </li>
                        </ul>
                     </div>
                     <p id="d0e276602"><b><a href="mpep-9020-appx-r.html#d0e332100">37 CFR 1.740</a></b> sets
                        forth the requirements for a formal application for extension of patent term. See
                        <b><a href="s2752.html#d0e276312">MPEP ยง
                              2752</a></b> for a discussion of who may apply for a patent term
                        extension. See <b><a href="mpep-9020-appx-r.html#d0e332296">37 CFR 1.741</a></b> and <b><a href="s2754.html#d0e276732">MPEP
                              ยง&nbsp;2754</a></b> for a description of the information that must be
                        submitted in the patent term extension application in order to be accorded a filing date. 
                     </p>
                     <p id="d0e276617"><b><a href="mpep-9020-appx-r.html#d0e332100">37 CFR 1.740(a)(1)</a></b>
                        requires a complete identification of the approved product as by appropriate chemical and
                        generic name, physical structure or characteristics so as to enable the Director to make a
                        determination of whether the patent claims the approved product, or a method of using or
                        manufacturing the approved product.
                     </p>
                     <p id="d0e276628"><b><a href="mpep-9020-appx-r.html#d0e332100">37 CFR 1.740(a)(2)</a></b>
                        requires a complete identification of the federal statute including the applicable
                        provision of law under which the regulatory review occurred. When the regulatory review of
                        the product took place under more than one Federal statute, each appropriate statute should
                        be listed. This could apply to a situation where a human biological product is tested under
                        an investigational new drug (IND) application pursuant to the Federal Food, Drug, and
                        Cosmetic Act, but is approved under the Public Health Service Act; or to a situation where
                        approval is sought for use of a particular medical device with a specific drug product
                        which may require approval under more than a single provision of law. The product that
                        forms the basis of an application for patent term extension must be either a medical device
                        or a drug product; any extension will be granted based upon the review of the product as
                        either a medical device or a drug productit cannot be a combination of those separate
                        products. See the file history of U.S. Patent No. 4,428,744 for an example of the
                        application of this principle.
                     </p>
                     <p id="d0e276634">The date that a product receives
                        permission for commercial marketing or use (which must be identified pursuant to
                        <b><a href="mpep-9020-appx-r.html#d0e332100">37
                              CFR 1.740(a)(3)</a></b>) is generally the mailing date of the letter from the
                        regulatory agency indicating regulatory approval. For a food additive, the approval date is
                        generally the effective date stated in the regulation and the date the regulation is
                        published.
                     </p>
                     <p id="d0e276640"><b><a href="mpep-9020-appx-r.html#d0e332100">37 CFR 1.740(a)(4)</a></b>
                        provides that for drug products, each active ingredient must be identified and there must
                        be an indication of the use for which the product was approved. For each active ingredient,
                        a statement must be made that either the active ingredient was not previously approved for
                        commercial marketing or use under the Federal Food, Drug and Cosmetic Act, or that the
                        active ingredient was approved for commercial marketing or use (either alone or in
                        combination with other active ingredients) and the provision of law under which it was
                        approved. The information is especially necessary for a determination of eligibility where,
                        for example, the application is based on a second or subsequent approval of an active
                        ingredient, but the first approval for administration to a food-producing
                        animal.
                     </p>
                     <p id="d0e276646">In accordance with <b><a href="mpep-9020-appx-r.html#d0e332100">37 CFR
                              1.740(a)(5)</a></b>, the application must be submitted within the sixty day
                        period permitted for submission pursuant to <b><a href="mpep-9020-appx-r.html#d0e331971">37 CFR 1.720(f)</a></b>. If
                        the sixty day period ends on a Saturday, Sunday or Federal holiday, then the last day on
                        which the application could be submitted will be considered to be the next business day
                        following the Saturday, Sunday or Federal holiday. See <b><a href="mpep-9020-appx-r.html#d0e313698">37 CFR 1.7</a></b>. The
                        starting date of the sixty-day period as recited in <b><a href="mpep-9015-appx-l.html#d0e304016">35 U.S.C. 156(d)(1)</a></b>
                        has been clarified by the America Invents Act where the Act provides that, โ[f]or purposes
                        of determining the date on which a product receives permission under the second sentence of
                        this paragraph, if such permission is transmitted after 4:30 P.M., Eastern Time, on a
                        business day, or is transmitted on a day that is not a business day, the product shall be
                        deemed to receive such permission on the next business day. For purposes of the preceding
                        sentence, the term 'business day' means any Monday, Tuesday, Wednesday, Thursday, or
                        Friday, excluding any legal holiday under section 6103 of title 5.โ See Section 37 of the
                        American Invents Act and <b><a href="mpep-9015-appx-l.html#d0e303884">35 U.S.C. 156</a></b>. However, applicants are
                        cautioned to avoid filing an application for patent term extension on the last day for
                        filing to avoid the application being denied because the filing deadline was inadvertently
                        missed. 
                     </p>
                     <p id="d0e276658">The expiration date of the patent for
                        which an extension is sought as identified pursuant to <b><a href="mpep-9020-appx-r.html#d0e332100">37 CFR 1.740(a)(6)</a></b>
                        should be the expiration date according to the law (<b><a href="mpep-9015-appx-l.html#d0e303482">35 U.S.C. 154</a></b>) at the
                        time of filing of the application for patent term extension, and should include any patent
                        term adjustment under <b><a href="mpep-9015-appx-l.html#d0e303482">35 U.S.C. 154(b)</a></b>. 
                     </p>
                     <p id="d0e276670">Pursuant to <b><a href="mpep-9020-appx-r.html#d0e332147">37 CFR 1.740(a)(9)</a></b>,
                        the application for patent term extension need only explain how one product claim of the
                        patent claims the approved product, if there is a claim to the product. In addition, the
                        application need only explain how one method of use claim of the patent claims the method
                        of use of the approved product, if there is a claim to the method of use of the product.
                        Lastly, the application need only explain how one claim of the patent claims the method of
                        manufacturing the approved product, if there is a claim to the method of manufacturing the
                        approved product. At most, a showing explaining three claims is required. However, each
                        claim that claims the approved product, the method of use of the approved product, or the
                        method of manufacturing the approved product must be listed. See <b><a href="mpep-9015-appx-l.html#d0e303884">35 U.S.C.
                              156(d)(1)(B)</a></b>. 
                     </p>
                     <p id="d0e276676">The showing should clearly explain how
                        each listed claim reads on the approved product. For example, where a generic chemical
                        structure is used in the claim to define the claimed invention, a listing of variables and
                        substituents which correspond to the approved product is appropriate. Where a claim uses
                        the โmeans forโ language permitted by <b><a href="mpep-9015-appx-l.html#d0e302824">35 U.S.C. 112, paragraph 6</a></b>, or
                        <b><a href="mpep-9015-appx-l.html#al_d1d85b_2ae7b_ec">35
                              U.S.C. 112(f)</a></b> for patents granted on AIA applications, reference to
                        the column and line number of the patent text and any drawing reference numbers, as well as
                        a description of any relevant equivalents, is also appropriate.
                     </p>
                     <p id="d0e276682">Pursuant to <b><a href="mpep-9020-appx-r.html#d0e332100">37 CFR
                              1.740(a)(10)</a></b>, the patent term extension applicant must provide a
                        statement to enable the Secretary of Health and Human Services or the Secretary of
                        Agriculture, as appropriate, to determine the applicable regulatory period. In cases where
                        there is no regulatory event to reflect the commencement of the testing or approval phase
                        of the regulatory review period, applicants should include in the application the dates
                        that they claim initiate either the approval or the testing phases and an explanation of
                        their reasonable bases for why they conclude that these dates are the relevant dates. For
                        instance, when the clinical trials are conducted outside of the United States, the testing
                        phase for a medical device begins on the date the clinical investigation involving the
                        device began. An applicant should include an explanation as to why the date claimed is the
                        date on which such clinical investigations had commenced. If the applicant has any means of
                        substantiating that date, that information should be included in the
                        application.
                     </p>
                     <p id="d0e276688"><b><a href="mpep-9020-appx-r.html#d0e332100">37 CFR 1.740(a)(11)</a></b>
                        requires a brief description of the activities of the marketing applicant before the
                        regulatory agency. This description should include an identification of significant
                        communications of substance with the regulatory agency and the dates related to such
                        communications. For example, these activities would include the dates of the submissions of
                        new data to the FDA, communications between FDA and the applicant with respect to the
                        appropriate protocols for testing the product, and communications between FDA and the
                        applicant that are attempts to define the particular requirements for premarketing approval
                        for this particular product. The applicant is not required to establish the existence of
                        due diligence during the regulatory review period in order to have a complete
                        application.
                     </p>
                     <p id="d0e276694">As stated above, the marketing
                        applicant must have been an agent of the patent owner, if not the same entity as the patent
                        owner. Accordingly, the Office will not assist the patent owner in obtaining information
                        required in an application for patent term extension from the marketing applicant. It is
                        sufficient that the description of the activities briefly identify those significant
                        activities undertaken by the marketing applicant directed toward regulatory approval, and a
                        submission of insignificant details or identification of non-substantive communications is
                        not required.
                     </p>
                     <p id="d0e276697"><b><a href="mpep-9020-appx-r.html#d0e332100">37 CFR 1.740(a)(12)</a></b>
                        requires that the extension applicant state the length of extension claimed and show how
                        the length of extension was calculated, including whether the 14-year limit of
                        <b><a href="mpep-9015-appx-l.html#d0e303884">35
                              U.S.C. 156(c)(3)</a></b> or the five-year limit of <b><a href="mpep-9015-appx-l.html#d0e304298">35 U.S.C.
                              156(g)(6)(A)</a></b> applies.
                     </p>
                     <p id="d0e276709"><b><a href="mpep-9020-appx-r.html#d0e332100">37 CFR 1.740(a)(15)</a></b>
                        requires the patent term extension applicant to provide a correspondence address. A fax
                        number should also be provided. Normally only communications regarding the application for
                        patent term extension will be sent to the address specified in the patent term extension
                        application. If the address is changed after filing the application for patent term
                        extension, the change of address should be sent to Mail Stop Hatch-Waxman PTE, since
                        changing the address for the patent file will not cause the address for the patent term
                        extension application to also be changed.
                     </p>
                     <p id="d0e276720">In order to change the address of all
                        correspondence, including maintenance fee reminders, a change of address should also be
                        filed. A change of address must be signed by the patent applicant, the assignee of the
                        entire interest, or an attorney or agent of record. <b><a href="mpep-9020-appx-r.html#d0e317491">37 CFR 1.33(a)</a></b>.
                        Accordingly, if the patent term extension application is signed by the marketing applicant,
                        as an agent of the patent owner, a power of attorney from the patent owner to any attorney
                        for the marketing applicant would be necessary for the attorney for the marketing applicant
                        to be able to sign a change of address for the patent file. 
                     </p>
                     <p id="d0e276726">Pursuant to <b><a href="mpep-9020-appx-r.html#d0e332100">37 CFR
                              1.740(b)</a></b>, two additional copies of the application for patent term
                        extension must be filed with the application. The original copy, along with the patent file
                        (if not already scanned into the Image File Wrapper system), is scanned into the Image File
                        Wrapper system so that all patent prosecution and patent term extension documents are
                        available in PUBLIC PAIR. One copy of the application is forwarded to the regulatory agency
                        and the second copy is used by the Legal Advisor in the Office of Patent Legal
                        Administration.
                     </p>
                     <p align="right"><a href="#top">[top]</a></p>
                  </div>
               </div>
               <div>
                  <h1 class="page-title">&nbsp;</h1>
               </div>  </div>
            </div>
         </div>
      </div>
      <div class="yui-b">
         <div id="aside">  <div id="rdms-sub-nav-container" xmlns:bf="http://www.uspto.gov/bf">
            <ul id="sub-nav">
               <li xmlns=""><a href="s2701.html">2701-Patent Term</a></li>
               <li xmlns=""><a href="s2702-2709.html">2702-2709-[Reserved]</a></li>
               <li xmlns=""><a href="s2710.html">2710-Term Extensions or Adjustments for Delays Within the USPTO Under 35 U.S.C. 154</a></li>
               <li xmlns=""><a href="s2711-2719.html">2711-2719-[Reserved]</a></li>
               <li xmlns=""><a href="s2720.html">2720-Applications Filed Between June 8, 1995, and May 28, 2000</a></li>
               <li xmlns=""><a href="s2721-2729.html">2721-2729-[Reserved]</a></li>
               <li xmlns=""><a href="s2730.html">2730-Applications Filed on or After May 29, 2000; Grounds for Adjustment</a></li>
               <li xmlns=""><a href="s2731.html">2731-Period of Adjustment</a></li>
               <li xmlns=""><a href="s2732.html">2732-Reduction of Period of Adjustment of Patent Term</a></li>
               <li xmlns=""><a href="s2733.html">2733-Patent Term Adjustment Determination</a></li>
               <li xmlns=""><a href="s2734.html">2734-Application for Patent Term Adjustment; Due Care Showing</a></li>
               <li xmlns=""><a href="s2735.html">2735-[Reserved]</a></li>
               <li xmlns=""><a href="s2736.html">2736-Third Party Papers</a></li>
               <li xmlns=""><a href="s2737-2749.html">2737-2749-[Reserved]</a></li>
               <li xmlns=""><a href="s2750.html">2750-Patent Term Extension for Delays at other Agencies under 35 U.S.C. 156</a></li>
               <li xmlns=""><a href="s2751.html">2751-Eligibility Requirements</a></li>
               <li xmlns=""><a href="s2752.html">2752-Patent Term Extension Applicant</a></li>
               <li xmlns=""><a href="s2753.html">2753-Application Contents</a></li>
               <li xmlns=""><a href="s2754.html">2754-Filing Date</a><ul>
                     <li><a href="s2754.html#d0e276883">2754.01-Deadline for Filing an Application Under 35 U.S.C. 156(d)(1)</a></li>
                     <li><a href="s2754.html#d0e276901">2754.02-Filing Window for an Application Under 35 U.S.C. 156(d)(5)</a></li>
                     <li><a href="s2754.html#d0e276937">2754.03-Filing of a Request for an Extension Under 35 U.S.C. 156(e)(2)</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2755.html">2755-Eligibility Determination</a><ul>
                     <li><a href="s2755.html#d0e276994">2755.01-Interim Extension of Patent Term During the Processing of the Application</a></li>
                     <li><a href="s2755.html#d0e277100">2755.02-Interim Extension of Patent Term Before Product Approval</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2756.html">2756-Correspondence Between the USPTO and the Regulatory Agency</a></li>
               <li xmlns=""><a href="s2757.html">2757-Regulatory Agency Determination of the Length of the Regulatory Review Period</a><ul>
                     <li><a href="s2757.html#d0e277434">2757.01-Due Diligence Determination</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2758.html">2758-Notice of Final Determination - Calculation of Patent Term Extension</a></li>
               <li xmlns=""><a href="s2759.html">2759-Certificate of Extension of Patent Term</a></li>
               <li xmlns=""><a href="s2760.html">2760-Trade Secret, Confidential, and Protective Order Material</a></li>
               <li xmlns=""><a href="s2761.html">2761-Multiple Applications for Extension of Term of the Same Patent or of Different Patents for the Same Regulatory Review Period
                     for a Product</a></li>
               <li xmlns=""><a href="s2762.html">2762-Duty of Disclosure in Patent Term Extension Proceedings</a></li>
               <li xmlns=""><a href="s2763.html">2763-Limitation of Third Party Participation</a></li>
               <li xmlns=""><a href="s2764.html">2764-Express Withdrawal of Application for Extension of Patent Term</a></li>
            </ul>  </div>
         </div>
      </div>  </div>
      

  <div style="text-align:right"> Last Modified: 

     

    03/27/2014 10:10:35 

  </div>

</div>

</div>




<!-- End of footer2.html -->


   </body>
</html>